Ian joins Optibrium having previously served as Head of Technology and Delivery for an insurance technology start-up, Hx—part of the Howden Group—where he developed innovative data, analytics and digital application-focused strategies through cloud platform delivery, as well as defining a target operating model to implement the Group’s data transformation and growth objectives. Prior to this, Ian worked at Merck, Sharp and Dohme (MSD), holding positions including Director of Research and Development Analytics, Director of IT Productivity and Director of Scientific Modelling & Real-World Data. During his tenure as Director R&D Analytics, Ian led a team to define, develop and execute an 18-month strategy to build Merck’s next-generation machine learning and AI-driven analytics platform and data science capabilities to mature research and develop scientific insights.
Ian Smith, Chief Technology Officer, Optibrium, commented: “I’m excited to join Optibrium at a time of significant growth and success as the Company’s technologies drive computer-aided drug discovery across the biotech industry. I look forward to working with a world-class team to develop our innovative platforms, further transforming customers’ drug discovery programmes.”
Edmund Champness, Chief Scientific Officer, Optibrium, said: “We are delighted to welcome Ian to the team to support the scale-up of our infrastructure and technical teams and to lead the development and deployment of our next-generation solutions. Ian brings an impressive combination of experience in cloud engineering, platform development and the pharma industry, which will be invaluable as we continue to expand our computational drug discovery platforms.”
For further information on Optibrium, please visit www.optibrium.com
, contact firstname.lastname@example.org
or call +44 1223 815900.